Full-Time
Develops monoclonal antibodies for infectious diseases
$242k - $329.5k/yr
Expert
San Francisco, CA, USA
This is an on-site position in our San Francisco Headquarters.
Upload your resume to see how it matches 3 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and government agencies to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.
Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.
Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.
Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.